EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Baseline [18F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy

Carla Oliveira iD, Francisco Oliveira iD, Cláudia Constantino iD, Celeste Alves iD, Maria José Brito iD, Fátima Cardoso iD, Durval C Costa iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06815-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Carla Oliveira und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal. carla.oliveira@fundacaochampalimaud.pt. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Neoadjuvant Therapy, Breast Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To verify the ability of pretreatment [ 18 F]FDG PET/CT and T1-weighed dynamic contrast-enhanced MRI to predict pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients.

Methods

This retrospective study includes patients with BC of no special type submitted to baseline [ 18 F]FDG PET/CT, NAC and surgery. [ 18 F]FDG PET-based features reflecting intensity and heterogeneity of tracer uptake were extracted from the primary BC and suspicious axillary lymph nodes (ALN), for comparative analysis related to NAC response (pCR vs. non-pCR). Multivariate logistic regression was performed for response prediction combining the breast tumor-extracted PET-based features and clinicopathological features. A subanalysis was performed in a patients’ subsample by adding breast tumor-extracted first-order MRI-based features to the multivariate logistic regression.

Results

A total of 170 tumors from 168 patients were included. pCR was observed in 60/170 tumors (20/107 luminal B-like, 25/45 triple-negative and 15/18 HER2-enriched surrogate molecular subtypes). Higher intensity and higher heterogeneity of [ 18 F]FDG uptake in the primary BC were associated with NAC response in HER2-negative tumors (immunohistochemistry score 0, 1 + or 2 + non-amplified by in situ hybridization). Also, higher intensity of tracer uptake was observed in ALN in the pCR group among HER2-negative tumors. No [ 18 F]FDG PET-based features were associated with pCR in the other subgroup analyses. A subsample of 103 tumors was also submitted to extraction of MRI-based features. When combined with clinicopathological features, neither [ 18 F]FDG PET nor MRI-based features had additional value for pCR prediction. The only significant predictors were estrogen receptor status, HER2 expression and grade.

Conclusion

Pretreatment [ 18 F]FDG PET-based features from primary BC and ALN are not associated with response to NAC, except in HER2-negative tumors. As compared with pathological features, no breast tumor-extracted PET or MRI-based feature improved response prediction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Neoadjuvant TherapyBreast NeoplasmsPositron Emission Tomography Computed TomographyMagnetic Resonance ImagingHumansFemaleMiddle AgedRetrospective StudiesAdultAgedTreatment OutcomeRadiopharmaceuticals

Stichwörter der Autor:innen

Breast cancerFirst-order featuresNeoadjuvant chemotherapyTreatment response prediction[18F]FDG PET/CTpCR prediction

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal. carla.oliveira@fundacaochampalimaud.pt.
  • Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
  • Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
  • Pathology Department, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.

ORCID-Profile: Carla Oliveira, Francisco Oliveira, Cláudia Constantino, Celeste Alves, Maria José Brito, Fátima Cardoso, Durval C Costa

Förderung

  • Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud

Zitieren

APA

Oliveira, C., Oliveira, F., Constantino, C., Alves, C., Brito, M. J., Cardoso, F., & Costa, D. C. (2024). Baseline [18F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06815-6

Vancouver

Oliveira C, Oliveira F, Constantino C, Alves C, Brito MJ, Cardoso F, et al. Baseline [18F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06815-6

BibTeX
@article{Oliveira2024,
  author = {Oliveira, Carla and Oliveira, Francisco and Constantino, Cláudia and Alves, Celeste and Brito, Maria José and Cardoso, Fátima and Costa, Durval C},
  title = {Baseline [18F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06815-6}
}
Kostenlos starten →